Case number | Timing | Upper left | Middle left | Lower left | Upper right | Middle right | Lower right | IP lesions in RT field | Possible triggers and/or other findings |
1 | Baseline | 0 | RT | RT | 0 | RT | RT | Pseudomonas aeruginosa pneumonia and synergistic lymphocyte activation by immunotherapy and RT | |
IP | 26–50% | 76–100% | 26–50% | 51–75% | 51–75% | 26–50% | 80% | ||
2 | Baseline | Lobectomy | M | 0 | RT (T) | 0 | T | Recall effect RT upper right and cryoablation lower left | |
IP | Lobectomy | 76–100% | 76–100% | 26–50% | 0 | 51–75% | 90% | ||
3 | Baseline | 0 | 0 | 0 | T | 0 | 0 | No specific trigger but close to T; no correlation with RT | |
IP | 0 | 0 | 0 | 1–25% | 0 | 0 | 0% | ||
4 | Baseline | 0 | 0 | 0 | 0 | 0 | RT (M) | Recall effect RT | |
IP | 26–50% | 1–25% | 1–25% | 26–50% | 26–50% | 51–75% | 60% | ||
5 | Baseline | 0 | 0 | 0 | 0 | 0 | 0 | Rhinovirus bronchiolitis 2 months before | |
IP | 26–50% | 26–50% | 26–50% | 26–50% | 26–50% | 26–50% | NA | ||
6 | Baseline | 0 | 0 | T | 0 | 0 | 0 | Marked in the T side; drug-induced pneumonia 6 months before | |
IP | 76–100% | 76–100% | 76–100% | 26–50% | 26–50% | 51–75% | NA | ||
7 | Baseline | 0 | T | 0 | 0 | 0 | 0 | NA | Marked in the T region |
IP | 51–75% | 76–100% | 76–100% | 26–50% | 26–50% | 26–50% | |||
8 | Baseline | 0 | 0 | M | RT (T) | RT | 0 | Marked in the M region; Pneumocystis jiroveci pneumonia 18 months before | |
IP | 0 | 1–25% | 26–50% | 26–50% | 0 | 0 | 25% | ||
9 | Baseline | 0 | 0 | 0 | 0 | RT (T) | RT | 100% | Lymphocyte activation by RT |
IP | 0 | 0 | 0 | 0 | 26–50% | 1–25% | |||
10 | Baseline | 0 | RT (T) | 0 | 0 | RT | 0 | Recall effect RT | |
IP | 76–100% | 76–100% | 1–25% | 26–50% | 26–50% | 1–25% | 80% | ||
11 | Baseline | 0 | 0 | 0 | M | 0 | 0 | No specific trigger but close to M | |
IP | 0 | 1–25% | 1–25% | 51–75% | 26–50% | 26–50% | NA | ||
12 | Baseline | 0 | 0 | 0 | RT (M) | 0 | 0 | Synergistic lymphocyte activation by immunotherapy and RT | |
IP | 1–25% | 26–50% | 0 | 26–50% | 26–50% | 0 | 75% | ||
13 | Baseline | RT | 0 | 0 | RT (T) | RT (T) | 0 | Recall effect RT | |
IP | 26–50% | 26–50% | 1–25% | 51–75% | 76–100% | 76–100% | 100% | ||
14 | Baseline | 0 | 0 | 0 | 0 | M | 0 | None | |
IP | 76–100% | 76–100% | 76–100% | 51–75% | 76–100% | 76–100% | NA | ||
15 | Baseline | RT | RT | RT | RT (T) | Lobectomy | RT (T) | Synergistic lymphocyte activation by immunotherapy and RT | |
IP | 26–50% | 26–50% | 51–75% | 51–75% | NA | 76–100% | 80% |
In patients who underwent radiation therapy, radiation therapy (RT) is used in the baseline row to identify the lung regions included in the radiation field. The tumour manifestation (primary tumour (T) or metastasis (M)) is added in parenthesis whenever the tumour manifestation was located in that irradiated region. NA: not available.